Markets:

Overview

News

Currencies

International

Treasuries

Estrella Immunopharma, Inc. - Common Stock (NQ:ESLA)

1.040 +0.090 (+9.46%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Estrella Immunopharma, Inc. - Common Stock

BioMedNewsBreaks – Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) Closes $8.0 Million Registered Direct Offering

January 07, 2026

Via Investor Brand Network

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

January 06, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

January 05, 2026

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

December 04, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

November 03, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

October 06, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

June 05, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

June 03, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas

May 29, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

March 05, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

February 21, 2025

From Estrella Immunopharma

Via Business Wire

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

February 19, 2025

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

September 27, 2024

From Estrella Immunopharma, Inc.

Via Business Wire

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

August 14, 2024

From Estrella Immunopharma, Inc.

Via Business Wire

BioMedNewsBreaks – Estrella Immunopharma Inc. (NASDAQ: ESLA, ESLAW) Starts Trading After TradeUP Acquisition Corp., Estrella Biopharma Inc. Business Combination

October 04, 2023

Via Investor Brand Network

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.